Apellis Pharmaceuticals Inc (APLS) Growth Rates Comparisons to Major Pharmaceutical Preparations Industry, Sector, Market. Sales, Income, EPS
CSIMarket
 
Apellis Pharmaceuticals Inc   (NASDAQ: APLS)
 

Apellis Pharmaceuticals Inc Growth Comparisons

Select each growth Category to receive further Information





APLS Revenue Growth Rate Comparisons Company Industry Sector S&P 500
Y / Y Revenue Growth (Q1 MRQ) 60.85 % 12.22 % 8.96 % 10.9 %
Q / Q Revenue Growth (Q1 MRQ) 34.21 % -2.93 % -5.51 % 8.32 %
Y / Y Revenue Growth (for 12 months ending Q1 TTM) 42.46 % 9.25 % 8.62 % %
Sequential Revenue Growth (for 12 months ending Q1 TTM) 10.11 % 2.69 % 2.02 % 2.61 %
Revenue 5 Year Average Growth 31.98 % 8.75 % 9.34 % 13.48 %


APLS's Growth Comparisons in I. Quarter 2026




Apellis Pharmaceuticals Inc showed respectable 60.85% year on year rise of Revenue in the first quarter 2026, comparing favorably to the 12.22% rise in the Major Pharmaceutical Preparations industry, and 8.96% growth in the Healthcare sector. Comparing the first quarter sales growth, both Major Pharmaceutical Preparations industry and Apellis Pharmaceuticals Inc outperformed 10.9% overall market increase.

Company's sequential top-line increase was 34.21% from the fourth quarter. Average annual sales rise for Apellis Pharmaceuticals Inc is 31.98%, while S & P 500's average yearly sales growth is 13.48% over the five years, including only Businesses with the first quarter 2026 Results.

APLS Growth Rates by Company's Segments

Segment Name
Y / Y
Sequential
EMPAVELI
109.32 %
-
SYFOVRE
15.78 %
-
Product revenue net
-
-
Fees And Patient Assistance
25.06 %
-
Government Other Rebates and Chargebacks
79.54 %
-
Returns
52.91 %
-
Product Revenue Allowance and Reserves
61.47 %
-
Reported Segment
60.85 %
-
Total
60.85 %
-73.27 %


Growth Rates of APLS's Income in the first quarter 2026


APLS Operating Income Growth Rates Comparisons Company Industry Sector S&P 500
Y / Y Operating Income Change (Q1 MRQ) - -8.88 % 4.74 % 97.6 %
Sequential Operating Income Change (Q1 MRQ) - -4.52 % 1.4 % 48.13 %
Y / Y Operating Income Growth (Q1 TTM) - 30.63 % 30.7 % 40.67 %
Sequential Operating Income Growth (Q1 TTM) 198.09 % -2.27 % 4.82 % 20.86 %
Operating Income 5 Year Avg. Change - 14.98 % 10.62 % 28.66 %


Income from Cont. Ops. Growth Rates Comparisons Company Industry Sector S&P 500
Y / Y Income from Cont. Ops. Change (Q1 MRQ) - -34.9 % -26.28 % 90.69 %
Sequential Income from Cont. Ops. Change (Q1 MRQ) - -2.61 % -66.2 % 27.07 %
Y / Y Income from Cont. Ops. Change (Q1 TTM) - 6.3 % 2.7 % 57.33 %
Sequential Income from Cont. Ops. Change (Q1 TTM) 495.27 % -10.02 % -5.02 % 18.65 %
Income from Cont. Ops. 5 Year Avg. Change - 14.8 % 8.95 % -24.17 %

APLS Net Income Growth Rates Comparisons Company Industry Sector S&P 500
Y / Y Net Income Growth (Q1 MRQ) - -35.09 % -26.24 % 90.69 %
Q / Q Net Income Growth (Q1 MRQ) - 2.87 % -1.54 % 27.07 %
Y / Y Net Income Change (Q1 TTM) - 5.27 % 15.53 % 57.33 %
Sequential Net Income Change (Q1 TTM) 495.27 % -10.16 % -6.71 % 18.65 %
Net Income 5 Year Avg. Growth - 14.99 % 9.41 % 30.75 %

APLS's EPS Growth Rates


EPS from Cont. Ops. Growth Rates Comparisons Company Industry Sector S&P 500
Y / Y EPS from Cont. Ops. Change (Q1 MRQ) - -40.27 % -26.28 % 90.69 %
Sequential EPS from Cont. Ops. Change (Q1 MRQ) - -7.72 % -66.2 % 27.07 %
Y / Y EPS from Cont. Ops. Change (Q1 TTM) - - - -
Sequential EPS from Cont. Ops. Change (Q1 TTM) 523.53 % - - 4.88 %
EPS from Cont. Ops. 5 Year Avg. Growth - 2.03 % 8.95 % -24.17 %



APLS EPS Net Growth Rates Comparisons Company Industry Sector S&P 500
Y / Y EPS Net Growth (Q1 MRQ) - -40.45 % -26.24 % -24.17 %
Q / Q EPS Net Growth (Q1 MRQ) - -2.53 % -1.54 % 27.07 %
Y / Y EPS Net Change (for 12 months ending Q1 TTM) - - - 7.62 %
Sequential EPS Net Change (for 12 months ending Q1 TTM) 593.33 % - - 4.93 %
EPS Net 5 Year Avg. Change - 14.99 % 9.41 % 30.75 %



Apellis Pharmaceuticals Inc reported bottom-line of $ 0.15 in the first quarter, compare to $ -0.74 in the same quarter a year ago. Major Pharmaceutical Preparations industry fell by -40.45%, while Healthcare sector decreased by -26.24%, and overall market improved by 90.69%.

The company's sequential bottom-line increase was 34.21% from the fourth quarter. Average annual income per share rise for Apellis Pharmaceuticals Inc is 31.98%, while S & P 500's average yearly income per share growth is 30.75% over the five years, including only Businesses with the first quarter 2026 earnings results.

APLS Cash Flow Growth Rates


Free Cash Flow Growth Rates Company Industry Sector S&P 500
Y / Y Free Cash Flow Change (Q1 MRQ) - 25.53 % 49.77 % 48.62 %
Sequential Free Cash Flow Change (Q1 MRQ) - -42.37 % -47.19 % 34.18 %
Y / Y Free Cash Flow Change (Q1 TTM) - 12.22 % 18.94 % 60.27 %
Sequential Free Cash Flow Change (Q1 TTM) -16.78 % 3.32 % 5.18 % 15.75 %
Free Cash Flow 5 Year Avg. Change - 3.5 % 1.82 % 18.38 %

Net Cash Flow Growth Rates Company Industry Sector S&P 500
Y / Y Net Cash Flow Change (Q1 MRQ) - - - 339.02 %
Sequential Net Cash Flow Change (Q1 MRQ) - - - 216.68 %
Y / Y Net Cash Flow Change (Q1 TTM) 42.98 % - - 209.43 %
Sequential Net Cash Flow Change (Q1 TTM) - - -86.74 % 152.64 %
Net Cash Flow 5 Year Avg. Change -23.83 % 29.18 % 6.07 % 4.29 %

Capital Expenditures Company Industry Sector S&P 500
Y / Y Capital Expenditures Change (Q1 MRQ) - 11.25 % 8.24 % 120.03 %
Sequential Capital Expenditures Change (Q1 MRQ) - -25.6 % -21.55 % 36.87 %
Y / Y Capital Expenditures Change (Q1 TTM) 158.47 % 18.04 % 8.45 % 109.38 %
Sequential Capital Expenditures Change (Q1 TTM) -2.56 % 4 % 2.15 % 23.05 %
Capital Expenditures 5 Year Avg. Change - 7.06 % 7.13 % 11.23 %

Note
To view Detail Information & Trends click on Individual Category.
To see Industry, Sector or S&P 500 Performance, click on each Category respectivly, on the top of the Table.

For explanation of terms visit: Glossary
 







Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.

© 2026 CSIMarket.com — Proprietary financial dataset. All rights reserved. Redistribution or automated extraction prohibited.